BioVie Inc. announced on July 9, 2025, that it presented data highlighting bezisterim’s potential to slow or reverse biological aging and neurodegeneration at the 7th World Aging and Rejuvenation Conference in Vienna, Austria. The presentation, titled 'Bezisterim Epigenetic Effects on Aging and Neurodegeneration,' featured as a keynote talk.
An analysis of 33 blood samples from patients in the company’s Phase 3 NM101 study for mild-to-moderate Alzheimer’s Disease revealed that patients treated with bezisterim potentially experienced an age deceleration advantage compared to placebo across 10 different biological clocks.
This data suggests a novel mechanism of action for bezisterim, modulating TNFα-driven inflammation to help reestablish homeostasis and affect multiple genes simultaneously. The findings indicate a potential to target epigenetic-driven age deceleration as a treatment for Alzheimer's and other neurodegenerative diseases of aging.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.